Similarly, by combining patients from two French multicentric trials, randomized by addition of adjuvant anthracycline-based therapy, a significant association between TILs and OS was not identified in HR+/HER2- breast tumors (30). This evidence concerns the gene ERBB2 and breast neoplasm.